{name}
{subtitle}
Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
city
~37 mi. (Lausanne, Switzerland, +199 more cities)
facility
CHUV (centre hospitalier universitaire vaudois) ( Site 0712)
Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)
city
~37 mi. (Lausanne, Switzerland, +34 more cities)
facility
CHUV (centre hospitalier universitaire vaudois) ( Site 0333)
drug
lenvatinib, +2 more drugs
drug type
immunotherapy, +1 more type
Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02)
city
~37 mi. (Lausanne, Switzerland, +21 more cities)
facility
CHUV Centre Hospitalier Universitaire Vaudois ( Site 4602)
drug
lenvatinib, +2 more drugs
drug type
immunotherapy, +1 more type
Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)
city
~37 mi. (Lausanne, Switzerland, +27 more cities)
facility
CHUV Centre Hospitalier Universitaire Vaudois ( Site 2602)
drug
lenvatinib, +3 more drugs
drug type
immunotherapy, +1 more type
Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)
city
~37 mi. (Lausanne, Switzerland, +30 more cities)
facility
CHUV Centre Hospitalier Universitaire Vaudois ( Site 1602)
drug
lenvatinib, +4 more drugs
drug type
immunotherapy, +2 more types
Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)
city
~37 mi. (Lausanne, Switzerland, +24 more cities)
facility
CHUV Centre Hospitalier Universitaire Vaudois ( Site 3602)
drug
MK-4830, +3 more drugs
CMP-001 and Pre-operative Stereotactic Body Radiation Therapy (SBRT) in Early Stage Triple Negative Breast Cancer (TNBC)
city
~37 mi. (Lausanne, Switzerland)
facility
CHUV Oncology Department
biomarker
ER Negative, +2 more biomarkers
drug
CMP-001, +1 more drug
drug type
immunotherapy, +2 more types
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
city
~58 mi. (Besançon, France, +144 more cities)
facility
CHU Jean Minjoz ( Site 1205)
drug
belzutifan, +3 more drugs
drug type
immunotherapy, +1 more type
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
city
~58 mi. (Besançon, France, +176 more cities)
facility
CHU Besancon - Hopital Jean Minjoz ( Site 2068)
condition
Endometrial Carcinoma, +1 more condition
drug
chemotherapy, +2 more drugs
drug type
chemotherapy, +2 more types
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
city
~58 mi. (Besançon, France, +226 more cities)
facility
CHU Jean Minjoz ( Site 0423)
drug
enzalutamide, +1 more drug
drug type
hormone therapy, +1 more type